Articles by George Koroneos, Online Content & News Editor - Pharmaceutical Executive


Articles by George Koroneos, Online Content & News Editor

Roche Shifts Execs in Anticipation of Departures

Sep 9, 2009

With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders.

An Open Conversation

Sep 1, 2009

Big Pharma navigates a regulatory minefield to reach social media consumers. It's anything but 'business as usual.'

A Hard Pill to Swallow

Aug 1, 2009

Innovative pharmaceutical companies are reaching out to physicians and consumers in an effort to get patients to take their medicine.

GSK Signs $120M Deal to Market DMab Overseas

Jul 30, 2009

Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved.

NHLBI Cans Sildenafil Study After Reports of Severe Pain

Jul 29, 2009

Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra.

Pfizer Joins Twitter Fray

Jul 29, 2009

The drug giant, last week, started tweeting about corporate initiatives, job openings, and news. Is Pfizer just jumping on the bandwagon, or is Twitter part of the company's social media strategy? Pharm Exec talks to Pfizer to find out more.

Sanofi Gets Green Light on Blockbuster Heart Treatment

Jul 8, 2009

Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.

FDA Boosts Warnings on Propoxyphene Pain Meds

Jul 8, 2009

Pain medications containing propoxyphene could lead to overdose and death, according to new labeling mandated by FDA. However, public requests to take these drugs (including Darvon and Darvocet) off the market have been denied.

Abbott to Pay $1.67B in Patent Suit

Jul 1, 2009

J&J emerged victorious in a patent suit claiming that the technology behind Abbott's blockbuster arthritis treatment Humira is too similar in design to J&J's Remicade. The cost to Abbott: $1.67 Billion.


Click here